<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211222053481N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-02-17</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Investigating The effect of melatonin on serum changes of Adropin in patients with diabetic retinopathy</public_title>
      <acronym></acronym>
      <scientific_title>Investigating The effect of melatonin on serum changes of Adropin in patients with diabetic retinopathy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-02-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>44</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/61932</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: In order to create balance in the number of samples assigned to each of the studied groups, the blocking method is used. This method is based on simple randomization. In this method, we first determine a total sample volume, then randomly assign a set of them to group A and assign the remainder to group B. For this purpose, Random Allocation Software will be used under Windows (Version 1.0). This method is based on determining the total sample size (44 people) and the number of groups (n = 2) and then randomly a set of them (22 people) to group A or intervention and the rest (22 people) to group B or Controls are assigned and then one of them is randomly selected without replacement, Blinding description: In this study, two groups of patients, a total of 44 patients with diabetic retinopathy aged 65 to 75 years referred to a charity hospital or eye treatment centers are selected and studied. 22 patients from the group of patients are randomly selected as the negative control group without melatonin and receiving only routine treatment (-Melatonin) and the remaining 22 will be selected as the treatment group (+ Melatonin) with melatonin in addition to routine treatment. Sampling is done before and after both groups, before the start of melatonin consumption and after the end of the course, and the samples are sent to the laboratory as a number (code) to measure the registered parameters and the answers are obtained for each serum number.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Diabetic Retinopathy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Diabetic patients with retinopathy. In this study, a total of 44 patients with diabetic retinopathy aged 65 to 75 years who are referred to Nikokary hospital is selected. Twenty-two patients will be randomly selected as the intervention group (+ Melatonin). The intervention group will receive 3 mg of oral melatonin capsule (Norm Life Melatonin Vanatonin) for 60 days in addition to their normal and routine treatment. Before the start of melatonin administration and at the end of the study course, on day 60, blood samples will be taken from both intervention and control patient groups. Finally, the collected serums will be biochemically analyzed and the results will be statistically analyzed along with the results obtained from clinical examinations, and finally, the results will be extracted and reported. Intervention 2: Control group: 22 patients will be randomly assigned to the negative control group without melatonin and only their usual treatment. Blood samples will be taken from both study groups before the start of the study and after the end of the course, ie on the 60th day. Finally, the collected serums will be biochemically analyzed and the results will be statistically analyzed along with the results obtained from clinical examinations, and finally, the results will be extracted and reported.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Alireza Javadzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tabriz university of medical sciences, university Ave,</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614766</zip>
        <telephone>+98 41 3442 6078</telephone>
        <email>javadzadeha@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Alireza Javadzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tabriz Univesity of Medical Sciences</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614766</zip>
        <telephone>+98 41 1336 4666</telephone>
        <email>javadzadeha@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with diabetic retinopathy
Patients without a history of melatonin use
Age range 65 to 75 years</inclusion_criteria>
      <agemin>65 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of melatonin use
History of using antioxidant compounds such as doxium
Has not consumed the essential elements with antioxidant properties
Antioxidant vitamins such as vitamins C and E.Not consumed</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E08.311</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Diabetic patients with retinopathy. In this study, a total of 44 patients with diabetic retinopathy aged 65 to 75 years who are referred to Nikokary hospital is selected. Twenty-two patients will be randomly selected as the intervention group (+ Melatonin). The intervention group will receive 3 mg of oral melatonin capsule (Norm Life Melatonin Vanatonin) for 60 days in addition to their normal and routine treatment. Before the start of melatonin administration and at the end of the study course, on day 60, blood samples will be taken from both intervention and control patient groups. Finally, the collected serums will be biochemically analyzed and the results will be statistically analyzed along with the results obtained from clinical examinations, and finally, the results will be extracted and reported.</i_keyword>
      <i_keyword>Control group: 22 patients will be randomly assigned to the negative control group without melatonin and only their usual treatment. Blood samples will be taken from both study groups before the start of the study and after the end of the course, ie on the 60th day. Finally, the collected serums will be biochemically analyzed and the results will be statistically analyzed along with the results obtained from clinical examinations, and finally, the results will be extracted and reported.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Serum changes of Adropin. Timepoint: Measurement of serum Adropin levels before intervention and 60 days after melatonin administration. Method of measurement: ELISA Method.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-02-02</approval_date>
        <contact_name>Ethics committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Daneshghah Ave. Tabriz University of Medical Sciences Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
